- Advertisement -spot_img
Friday, January 27, 2023

Study: Moderna COVID-19 immunity lasts for 6 months

September 14 (WNN)—— A small study published on Tuesday in the journal Science found that the immunity of the Moderna COVID-19 vaccine can last at least six months, and there is no indication that fully vaccinated people need booster shots.

The data shows that the vaccine seems to also produce durable protection against the coronavirus in people of all ages, including those 70 years of age and older who are at higher risk of serious diseases.

“Immune memory is stable, which is impressive,” co-author Shane Crotty said in a press release.

Crotty, a professor of vaccine research at the La Jolla Institute, said, “This is a good indicator of the durability of Moderna and Pfizer-BioNTech vaccines made with similar formulations.”

The researchers said these findings are based on an analysis of 35 people who participated in early clinical trials of the vaccine. They received the low-dose version, which is equivalent to a quarter of the 100 microgram dose now given.

“We want to see if a quarter of the dose can induce any immune response,” study co-author Jose Mateus Triviño said in a press release.

Mateus Triviño, a postdoctoral researcher at the La Jolla Institute in California, said: “We have the opportunity to obtain samples from participants in the initial phase 1 trial, who received two 25 micrograms of vaccine injections. , 28 days apart.”.

The data released by the company showed that clinical trials conducted on patients receiving full doses of Moderna vaccine found that the vaccine provided 93% protection against serious diseases for at least six months.

Although Moderna vaccines and Johnson & Johnson and Pfizer BioNTech vaccines reduce the risk of serious diseases, even with the more dangerous Delta variants, they may be less effective, and immunity may begin to weaken for several months in as little as 4 years. research shows.

In this study, researchers at the La Jolla Institute compared the immunity of recovered COVID-19 patients with the immunity of vaccine trial participants who received a 25 microgram dose of Moderna vaccine during a phase 1 clinical trial.

This dose is one-fourth of the 100 microgram Moderna dose urgently authorized by the US Food and Drug Administration in December last year.

The researchers said that most of the 35 patients included in the analysis maintained a high antibody response six months after being fully vaccinated.

Antibodies are cells produced by the immune system to fight viruses.

Researchers say that six months is enough time for the body to produce an “immune memory” against COVID-19, which means that the protection provided by the vaccine can last longer.

They said this indicates that the Moderna vaccine may not require booster injections, which has caused controversy in view of the shortage of vaccines in some parts of the world, especially at full doses.

In addition, the researchers found that the Moderna vaccine stimulates an adaptive immune response to the virus, which is almost the same as the natural response to infection.

Researchers say that it seems to also enhance the immune response to the common cold caused by the coronavirus, further enhancing protection.

However, the study did not show that the lower dose of Moderna vaccine provides the same protection as the standard dose, because doing so requires clinical trials.

He and his colleagues plan to see if other COVID-19 vaccines will produce the same, long-lasting immune response, even though “real world” data suggests they do.

“The people in the hospital are those who have not been vaccinated,” said Daniela Weiskopf, a co-author of the study and assistant professor of immunology in La Jolla.

.

World Nation News Desk
World Nation News Deskhttps://worldnationnews.com/
World Nation News is a digital news portal website. Which provides important and latest breaking news updates to our audience in an effective and efficient ways, like world’s top stories, entertainment, sports, technology and much more news.
Latest news
Related news
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here